Sarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at Needham & Company LLC in a report issued on Tuesday,Benzinga reports. They currently have a $202.00 target price on the biotechnology company's stock. Needham & Company LLC's target price indicates a potential upside of 69.99% from the company's current price.

Several other research firms have also commented on SRPT. Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. UBS Group lifted their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. Royal Bank of Canada restated an "outperform" rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Evercore ISI cut their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. Finally, Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a "buy" rating and a $165.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $178.71.

Sarepta Therapeutics Stock Performance

SRPT stock traded up $0.40 on Tuesday, hitting $118.83. The company had a trading volume of 1,297,109 shares, compared to its average volume of 815,589. The stock has a market cap of $11.35 billion, a price-to-earnings ratio of 95.06 and a beta of 0.77. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock's 50-day simple moving average is $122.04 and its 200 day simple moving average is $130.41. Sarepta Therapeutics has a 12-month low of $102.15 and a 12-month high of $173.25.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of the firm's stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company's stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Park Avenue Securities LLC purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $205,000. Harbor Capital Advisors Inc. lifted its stake in Sarepta Therapeutics by 33.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,706 shares of the biotechnology company's stock valued at $207,000 after buying an additional 427 shares in the last quarter. ORG Partners LLC boosted its holdings in Sarepta Therapeutics by 17.6% in the 4th quarter. ORG Partners LLC now owns 2,000 shares of the biotechnology company's stock worth $243,000 after buying an additional 300 shares during the last quarter. Nordea Investment Management AB increased its stake in Sarepta Therapeutics by 19.1% during the 4th quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock worth $8,228,000 after buying an additional 10,815 shares in the last quarter. Finally, Everence Capital Management Inc. purchased a new stake in Sarepta Therapeutics during the 4th quarter worth approximately $344,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.